<DOC>
<DOCNO>en.3.398.49.2007.10.19</DOCNO>
<TITLE> Europe stocks dip on credit woes, AstraZeneca sags </TITLE>
<TEXT>
 PARIS, Oct 19 (bdnews24.com/Reuters) - European stocks retreated on Friday, falling to a two-week low as worries over the impact of the squeeze in the credit market hit banking shares, while disappointing U.S. earnings spurred concerns over the economy. AstraZeneca Plc tumbled 3.8 percent after the European Patent Office revoked a key patent on its key asthma drug Symbicort, putting at risk future sales of the blockbuster, which sold $1.02 billion in Europe last year. The FTSEurofirst 300 index of top European shares unofficially closed 0.6 percent lower at 1,564.44 points, after rising to as much as 1,575.89 in early trade. Banks slipped, with Royal Bank of Scotland losing 2.1 percent, HBOS falling 3 percent and BNP Paribas dropping 1.3 percent. U.S. bank Wachovia Corp posted quarterly results that missed forecasts on Friday, as it suffered $1.3 billion of write-downs at its investment banking unit. The results added to a dismal week for large U.S. banks, which have been hammered by increases in bad loans, and capital market disruptions that resulted in trading losses. The mood was also dampened by oil prices hurdling the $90-a-barrel mark, fuelling inflation worries, and after the euro rose to an all-time high against the dollar, putting pressure on shares of European exporters. "Credit market concerns are still dominating sentiment, with strong safe haven demand boosting government debt, steepening curves and harrying the dollar," Bear Stearns analysts wrote in a note. "There are unlikely to be any rescue remedies coming through from this weekend's G7 summi
</TEXT>
</DOC>
